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Abstract 26 
 27 
Aims: The main objective of the study is molecular and biological characterization of 28 
the human-yeast hybrid squalene synthase, as a promising target for treatment of 29 
hypercholesterolemia. 30 
Methods and Results: The human-yeast hybrid squalene synthase, with 67% amino 31 
acids, including the catalytic site derived from human enzyme, was expressed in S. 32 
cerevisiae strain deleted of its own squalene synthase gene. The constructed strain has a 33 
decreased level of sterols compared to the control strain. The mevalonate pathway and 34 
sterol biosynthesis genes are induced and the level of triacylglycerols is increased. 35 
Treatment of the strain with rosuvastatin or zaragozic acid, two mevalonate pathway 36 
inhibitors, decreased the amounts of squalene, lanosterol and ergosterol, and up-37 
regulated expression of several genes encoding enzymes responsible for biosynthesis of 38 
ergosterol precursors. Conversely, expression of the majority genes implicated in the 39 
biosynthesis of other mevalonate pathway end-products, ubiquinone and dolichol, was 40 
down-regulated. 41 
Conclusions: The S. cerevisiae strain constructed in this study enables to investigate 42 
the physiological and molecular effects of inhibitors on cell functioning. 43 
Significance and Impact of the Study: The yeast strain expressing hybrid squalene 44 
synthase with the catalytic core of human enzyme is a convenient tool for efficient 45 
screening for novel inhibitors of cholesterol-lowering properties. 46 
 47 
Keywords: mevalonate pathway, squalene synthase, sterol biosynthesis inhibitors, 48 
yeast expression system, heterologous proteins 49 
50 
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Introduction 51 
Conversion of HMG-CoA to mevalonate is an early step in the cholesterol biosynthesis. 52 
Mevalonate is also a precursor for biologically important nonsteroidal isoprenoids, for 53 
example: dolichol, ubiquinone, isopentenyl tRNA and prenylated proteins, which have 54 
an important role in the regulation of cellular processes. Statins, by competitive 55 
inhibition of the HMG-Co reductase (HMGR) reduce endogenous cholesterol 56 
production, increase the number of LDL receptors and thereby lower the serum 57 
cholesterol level (Opie 2015). Although statin therapy is commonly assumed to be well 58 
tolerated, serious adverse effects have been reported. Therefore, it is postulated that 59 
some statins side effects may be due to the fact that statins suppress all post mevalonate 60 
biosynthesis steps including non-steroidal isoprenoids (Charlton-Menys and Durrington 61 
2008). Probably inhibition of HMGR, a key regulator of the mevalonic acid pathway, 62 
causes not only decrease of cholesterol biosynthesis, but also disturbances in the 63 
synthesis of other molecules like isopentyl diphosphate, farnesyl diphosphate and 64 
geranylgeranyl diphosphate. Hence, there is a need for new medicines to lower 65 
cholesterol levels, without any serious adverse reactions and also effective against 66 
hypercholesterolemia (Seiki and Frishman 2009). 67 
In both humans and yeast the mevalonate pathways are highly conserved (Fig. 68 
1). They are identical till the zymosterol formation with the end product in human cells 69 
being cholesterol, and ergosterol in yeast. The use of yeast as a host for the expression 70 
of heterologous proteins has become increasingly popular in recent years (Nielsen 71 
2009). As an eukaryote, S. cerevisae has many of the advantages of higher eukaryotic 72 
expression systems such as protein processing, protein folding and posttranslational 73 
modifications, while being as easy to manipulate as the bacteria E. coli. As a model of 74 
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fundamental cellular processes and metabolic pathways of the human, yeast have 75 
improved the understanding and facilitated the molecular analysis of many disease 76 
genes (Menacho-Márquez and Murguía 2007; Ruggles et al. 2014). Comparative 77 
genomics studies have shown that 40% of yeast proteins show homology to at least one 78 
human protein and 30% of genes involved in human disease pathology have an ortholog 79 
in yeast (Sturgeon 2006). Also, many regulatory pathways are conserved between yeast 80 
and humans. Therefore, yeast emerge as an attractive model in drug development 81 
studies like identification of new drug targets, target-based and non-target based drug 82 
screening and analysis of the cellular effects of drugs (Hughes 2002; Wysocka-83 
Kapcinska et al. 2009; Marjanovic et al. 2010). 84 
In our study, squalene synthase (SQS), the first dedicated enzyme of sterol 85 
biosynthesis, has been chosen as a promising target for treatment of 86 
hypercholesterolemia. Squalene sythase catalyzes the conversion of trans-farnesyl 87 
diphosphate to squalene, the first specific step in the cholesterol biosynthetic pathway, 88 
and is responsible for the flow of metabolites into either the sterol or the non sterol 89 
branch of the pathway (Do et al. 2009). Squalene synthase inhibitors (SSIs) reduced 90 
hepatic cholesterol biosynthesis by the induction of hepatic LDL receptors in a similar 91 
way to statins (Charlton-Menys and Durrington 2007). Several classes of squalene 92 
synthase inhibitors have been studied as potent inhibitors of squalene synthase 93 
(Kourounakis 2011). For example, the fungal metabolite zaragozic acids or sualestatins 94 
have been investigated as potent inhibitors of squalene synthase in human and other 95 
species (Liu et al. 2012). SSIs do not cause myotoxicity, and when administered 96 
together with a statin, reduce the statin-induced myotoxicity (Nishimoto et al. 2007). 97 
On the other hand, most of SSIs failed to pass clinical phase I/II trials because of their 98 
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hepatoxicity (Liao 2011). Nevertheless, squalene sythase is still considered as a 99 
promising target for therapeutic molecules that could decrease cholesterol level without 100 
affecting other isoprenoids. 101 
Yeast and human squalene synthase amino acid sequences show 36% amino 102 
acid identity and 57% similarity. Apart from the amino and carboxyl termini, which are 103 
not similar, the conservation of sequences responsible for the catalytic activity of the 104 
protein is very high (Robinson et al. 1993). The activity of squalene synthase is 105 
essential for cell growth in yeast (Jennings et al. 1991), and a deletion of the ERG9 gene 106 
encoding yeast SQS is lethal. It has been shown previously that human FDFT1 gene 107 
encoding hSQS expressed in yeast cells lacking native squalene synthase (erg9Δ) fails 108 
to restore viability of the defective strain (Robinson et al. 1993; Soltis et al. 1995). 109 
In this study, we present molecular and biological characterization of the human-110 
yeast hybrid squalene synthase, containing 67% of human SQS including the catalytic 111 
site. Moreover, we analyse the impact of selected mevalonate pathway inhibitors on the 112 
cell metabolism. Proposed by us, yeast model expressing hybrid squalene synthase with 113 
the catalytic core of human SQS allows rapid, inexpensive, highly efficient screening of 114 
in silico designed substances of cholesterol-lowering properties. Its application for such 115 
screening will result in elimination of molecules of less effectiveness or causing adverse 116 
effect. 117 
 118 
Materials and methods 119 
 120 
Media and growth conditions 121 
 6 
Saccharomyces cerevisiae strains were cultivated in standard YP medium (1% Bacto-122 
yeast extract, 1% Bacto-peptone) containing 2% dextrose (YPD), 3% glycerol (YPGly), 123 
or 3% ethanol (YPEtOH). Synthetic SD minimal medium (0.67% Bacto-yeast nitrogen 124 
base, 2% dextrose) supplemented with a required synthetic complete amino acids drop-125 
out mixture (Sunrise Science Products, San Diego, CA, USA) was used for selection of 126 
yeast cells bearing plasmids. Solid media were prepared by the addition of 2% Bacto-127 
agar. URA3 counter-selection of yeast was carried out on SD plates supplemented with 128 
0.1% 5-fluoroorotic acid (5-FOA; Sigma-Aldrich, St. Louis, MO, USA) and required 129 
amino acids. To select cells containing the kanMX4 cassette, YPD was supplemented 130 
with geneticin (G418 sulphate, Sigma-Aldrich) at the concentration of 200 μg ml-1. To 131 
induce membrane permeability, nystatin (Sigma-Aldrich) was added to YPD to the final 132 
concentration of 5 μg ml-1. Rosuvastatin stock solution (10 mg ml-1) was prepared by 133 
extracting an active substance from Crestor (AstraZeneca AB, Sweden), as described 134 
previously (Maciejak et al. 2013). Zaragozic acid (Sigma-Aldrich) was dissolved in 135 
DMSO to obtain 10 mg ml
-1
 stock solution. Yeast cells were grown aerobically either in 136 
liquid or on solid medium, at 28C. To perform growth curves overnight cultures were 137 
diluted to the concentration of 0.5x10
7
 cells/ml and cells were grown in SD-HIS 138 
medium at 28C for 14 hours. Optical density (OD600) measurements were done after 139 
every two hours of cultivation. Each culture was assayed in triplicate and the results 140 
were averaged. 141 
 142 
Homology modeling of human and yeast SQS structure 143 
Models of yeast and hybrid SQS fragments (34-383 and 35-376, respectively) were 144 
obtained using SYBYLx2.1, TRIPOS Inc., on the basis of human SQS structure (PDB 145 
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entry 3VJ8) (Liu et al. 2012). The model structures were subjected to staged energy 146 
minimization using AMBERFF99 forcefield, 100 steps. The model structure of 147 
zaragozic acid complexed with hybrid SQS was obtained on the basis of the structure of 148 
human SQS  in complex with zaragozic acid (3VJC), (Liu et al. 2012). 149 
 150 
DNA manipulations and plasmid construction 151 
Standard protocols were used for all DNA manipulations (Green and Sambrook 2012). 152 
The Escherichia coli strain XL1-Blue MRF’ (Stratagene, La Jolla, CA, USA) was used 153 
for cloning and propagation of plasmids. The sequences of all primers and methodology 154 
of plasmid construction are shown in the Supporting Information, Table S1 and Figure 155 
S1, respectively. The ERG9 gene, encoding yeast SQS, was amplified with BamERG9 156 
and ERG9SalI primers and ligated into pGEM-T Easy vector (Promega, Madison, WI, 157 
USA). The FDFT1 cDNA, encoding human SQS, was amplified with 1FDFTbam and 158 
2FDFTeco primers and ligated into pGEM-T Easy. The resulting plasmids served as 159 
templates to construct hybrid squalene synthase (HYB). Both plasmids were digested 160 
with MscI and SalI and the ERG9 MscI-SalI fragment was subcloned into MscI-SalI cut 161 
FDFT1/pGEM. Next, the resulting plasmid was digested with MscI and ligated with the 162 
MscI-MscI fragment of FDFT1 gene to form HYB/pGEM. Tagging of HYB sequence 163 
with 6HA was carried out by PCR-amplification of HYB from HYB/pGEM using 164 
HindHYB and HYBSalI primers and cloning into HindIII-SalI digested pYM16 (Janke 165 
et al. 2004). Next, the promoter of ERG9 gene, amplified with HinpERG9 and 166 
pERG9Hin primers, was introduced into HindIII site of HYBHA/pYM16 plasmid. 167 
Finally, PERG9-HYBHA was cloned into NotI and SmaI cut pRS313 (Sikorski and Hieter 168 
1989). The analogous vector carrying ERG9 tagged with 6HA was constructed by PCR-169 
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amplification of the PERG9-ERG9HA sequence with NotIERG9 and ERG9XmaI primers 170 
from genomic DNA of the ERG9HA strain (construction details in the Supplementary 171 
Material). The amplified PERG9-ERG9HA fragment was cloned into NotI-XmaI digested 172 
pRS313. 173 
 174 
Construction of yeast strains expressing recombinant squalene synthase 175 
The Saccharomyces cerevisiae BY4741 and heterozygous diploid erg9Δ/ERG9 in the 176 
background of BY4743 (EUROSCARF, Frankfurt, Germany) were used as the parental 177 
strains for yeast strains constructed in this study. All yeast strains are listed in the 178 
Supporting Information, Table S2. Yeast transformation was performed according to 179 
Gietz and Woods (2002). Heterozygous diploid erg9Δ/ERG9 was transformed with 180 
PGAL1-ERG9/pYES2 plasmid, sporulated and tetrads were dissected and cultured on 181 
YPD plates. Haploid erg9Δ [PGAL1-ERG9] was selected after replica plating on YPD 182 
supplemented with geneticin and SD-URA. This haploid served for further 183 
constructions of strains expressing yeast and hybrid squalene synthase. In order to 184 
construct the erg9Δ [PERG9-HYBHA] strain expressing human-yeast hybrid squalene 185 
synthase, the PERG9-HYBHA/pRS313 plasmid was transformed into erg9Δ [PGAL1-ERG9] 186 
strain. Subsequently, the PGAL1-ERG9/pYES2 plasmid was lost on SD-HIS plates 187 
containing 5-FOA to obtain the investigated strain. The erg9Δ [PERG9-ERG9HA] control 188 
strain was obtained by transformation of erg9Δ [PGAL1-ERG9] strain with PERG9-189 
ERG9HA/pRS313. Next, the PGAL1-ERG9/pYES2 plasmid was lost on SD-HIS plates 190 
containing 5-FOA. 191 
 192 
Lipid extraction  193 
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Yeast strains were grown in SD-HIS medium with or without an inhibitor, starting from 194 
0.5x10
7
 cells/ml. After 10 hours, cells were spun down, pellets were weighed and lipid 195 
extraction was performed according to the procedure described by Folch et al. (1957) 196 
with minor changes, namely 16 μg cholestanol/sample was added as an internal 197 
standard. Cells were homogenized with chloroform/methanol (1:1) and 0.063-0.200 mm 198 
Silica Gel 60 (Merck, Darmstadt, Germany) by 5 min vortexing and overnight shaking. 199 
Homogenates were spun down, solvent was removed to new tubes and remaining pellets 200 
were re-extracted twice for 5 hours. Extracts were pooled and washed three times with 201 
1/5 volume of 0.9% NaCl solution. The lower, chloroform phase containing lipids was 202 
transferred to new tube and the solvent was evaporated under a stream of nitrogen and 203 
dissolved in chloroform:methanol to yield crude lipid extract. For sterol analysis an 204 
aliquot of crude lipid extract was dried and hydrolyzed after supplementation with 205 
ethanol/toluene/water (82:100:15) solution with 7.5% KOH (w/v) for 2 hours at 100C. 206 
Lipids were extracted with equal volume of diethyl ether, the upper phase was 207 
transferred to a new tube and the lower phase was re-extracted twice with diethyl ether, 208 
then the extracts were polled and evaporated and lipids were dissolved in 500 μl hexane. 209 
 210 
GC/MS analysis of lipids 211 
The Agilent 5975C GC/MSD (a gas chromatograph and a mass spectrometer detector of 212 
Agilent Technologies, Santa Clara, CA) equipped with a 30 m long HP-5ms column, 213 
with 0.25 mm inner diameter, and 0.25 μm stationary phase film thickness were used. 1 214 
μl of lipid sample (hexane extract) was injected and the column temperature was set at 215 
150C for 5 min, next it was increased to 300C with the ramp of 5C/min and the final 216 
temperature was set at 300C for 30 min. Helium was used as a carrier gas and the flow 217 
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rate was set on 1 ml/min. The scan mode of 33-600 m/z was used to monitor mass 218 
spectra. Sterols were identified by comparing their spectra with the those of the NIST 219 
Mass Spectral Program (NIST/EPA/NIH Mass Spectral Library Version 2.0f). Area 220 
under the signals of sterol and of internal control (cholestanol) served to calculate the 221 
amount of sterol. 222 
 223 
TLC lipid analysis 224 
A thin layer chromatography (TLC) was carried out for crude lipid extract. Samples 225 
were evaporated and dissolved in the appropriate amount of chloroform so that an equal 226 
concentration of total lipids in each sample was achieved. 50 μl of each sample 227 
corresponding to 60 μg of wet yeast mass spotted on a TLC plate (Silica Gel 60 F254 228 
0.2 mm) and the plate was developed with petrol ether/diethyl ether/acetic acid 229 
(90:10:1) as a mobile phase. Subsequently, the plate was dried and lipids were 230 
visualized by iodine vapor. Densitometric analysis of freshly stained TLC 231 
chromatogram, covered with a glass plate to avoid iodine desorption, was performed to 232 
estimate the relative lipid content (ImageJ2x software, Java-based image processing 233 
program, developed at the National Institutes of Health). Lipids were identified by 234 
comparison with external standards. 235 
 236 
Quantitative real-time RT-PCR 237 
Yeast strains were grown in SD-HIS medium with or without an inhibitor, starting from 238 
0.5x10
7
 cells/ml. Each culture was prepared in three independent replicates. After 10 239 
hours, cells were harvested, homogenized with MagNA Lyser Instrument (Roche 240 
Diagnostics GmbH, Germany) and total RNA was isolated with MagNA Pure Compact 241 
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Instrument (Roche) according to the manufacturer’s instruction. cDNA was synthesized 242 
with QuantiTect Reverse Transcription Kit (Qiagen, Hilden, Germany), following the 243 
instruction. Primers used for RT-qPCR are presented in the Supporting Information, 244 
Table S3. RT-qPCR was carried out in 96-well plates using the LightCycler FastStart 245 
DNA Master SYBR Green I and the LightCycler 480 System (Roche). Each sample was 246 
run in triplicate. In order to calculate the relative expression ratio of genes between 247 
experimental and control samples, the Pfaffl model (Pfaffl 2001) was used and 248 
calculations were carried out in the REST-MCS v2 software tool. The expression data 249 
were normalized to the reference gene ACT1. All experiments were performed 250 
according to the MIQE guidelines (Bustin et al. 2009). 251 
 252 
Results  253 
 254 
Human and yeast SQS models show different structures 255 
A comparison of the modeled yeast SQS structure with that of the experimentally 256 
derived human SQS structure of the human and yeast SQS proteins showed no major 257 
differences around the active center, but significant structural alterations between the 258 
yeast fragments N113-D119 and D161-T171, and the corresponding human SQS 259 
regions M112-D118 and D159-S164 (Supporting Information, Fig. S2). These 260 
fragments are located in close proximity to the central cavity, so one may expect 261 
differences in the binding of inhibitors to the human and yeast squalene synthases. 262 
Taking into consideration all the above-mentioned aspects, a hybrid squalene synthase 263 
with the catalytic core of human SQS was constructed in this study. A model structure 264 
of the hybrid SQS was compared with the structure of human SQS. On the basis of 265 
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published data (Liu et al. 2012; Liu et al. 2014; Shang et al. 2014) it was established 266 
that residues constituting the active center of human SQS are located in fragment 35 - 267 
327 of the enzyme. Superposition of backbone atoms of the 35 -327 fragment gave an 268 
RMSD (root mean square deviation) of about 0.1 Å between the human and the hybrid 269 
enzyme, what means that both structures are virtually identical in that region. 270 
Differences between both structures appear at the C-terminal part of the protein, which 271 
is far away from the active site. Fig. 2 presents a comparison of the main chain course 272 
of the human and the hybrid SQS. The part of human SQS structure (P354 - K358) 273 
substantially different from the hybrid SQS is also shown. 274 
 275 
HYBHA hybrid gene restores erg9Δ viability 276 
S. cerevisiae erg9Δ strain bearing the FDFT1-ERG9 hybrid gene (HYBHA) was 277 
constructed similar to Robinson et al. (1993). The hybrid squalene synthase comprised 278 
67% of human SQS aa sequence (1-296 amino acids) including the catalytic site, and 279 
33% of yeast SQS sequence (304-444 amino acids), which included transmembrane 280 
domain necessary for the attachment of protein to the membranes of endoplasmic 281 
reticulum (Supporting Information, Fig. S3). Importantly, in our study the squalene 282 
synthase hybrid gene was expressed from the native ERG9 promoter, and was fused on 283 
its 3’ end with hemagglutinin (HA) tag sequence. The PERG9–HYBHA construct was 284 
cloned into centromeric pRS313 vector and was expressed in yeast erg9Δ strain. 285 
Control strains erg9Δ bearing PERG9–ERG9HA on pRS313 and BY4741 transformed 286 
with an empty pRS313 vector were also constructed. 287 
On the contrary to the full-length human FDFT1 gene, the human-yeast hybrid 288 
gene HYBHA was able to restore viability of erg9Δ yeast cells. All tested strains were 289 
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growing equally on a complete medium, a minimal (histidine lacking) medium and 290 
glycerol or ethanol containing medium at 28C (Fig. 3a). No statistically significant 291 
difference between the growth curves was observed (Fig. 3b). 292 
Additionally, all strains were tested on nystatin supplemented medium (Fig. 3c). 293 
Nystatin is a polyene macrolide antibiotic which forms ion channels on plasma 294 
membrane, resulting in cation leakage and cell death. The nystatin activity was shown 295 
to be significantly affected by the ergosterol membrane’s molar fraction (Kristanc et al. 296 
2014). The HYBHA expressing strain was resistant to nystatin, which might be due to 297 
lowered content of ergosterol in plasma membranes. 298 
 299 
Sterol biosynthesis is disturbed in HYBHA expressing strain 300 
To evaluate the level of squalene and sterol in yeast cells, gas chromatography/mass 301 
spectrometry (GC/MS) analysis of lipids was performed. The content of squalene, 302 
lanosterol and ergosterol was diminished in HYBHA expressing strain, and it reached 303 
the level of 10.9% (p=0.035), 43.7% (p=0.094) and 82.3% (p=0.342) respectively, in 304 
comparison to the control strain (Fig. 4a). 305 
Since the sterol biosynthesis was impaired in the erg9Δ [PERG9-HYBHA] strain, 306 
sterol storage forms might be modified as a result of diminished sterol content. Sterols 307 
are stored in yeast cells in the form of esters and they are located in lipid particles (LP) 308 
together with triacylglycerols (Czabany et al. 2007). As tested by semiquantitative thin 309 
layer chromatography method (TLC), the erg9Δ [PERG9-HYBHA] strain showed a 310 
different profile of lipids than the control (Fig. 4b). Both, the level of free ergosterol and 311 
also ergosterylesters was reduced. On the contrary, the level of triacylglycerols and free 312 
fatty acids was increased. 313 
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mRNA expression level of isoprenoid biosynthesis pathway genes is changed in 314 
HYBHA expressing strain 315 
Quantification of mRNA for genes encoding selected enzymes (shown in Fig. 1) from 316 
the sterol and non-sterol isoprenoid biosynthesis pathways was performed by RT-qPCR. 317 
Gene expression levels in the erg9Δ [PERG9-HYBHA] strain cultured at 28
o
C were 318 
related to the expression of respective genes in erg9Δ [PERG9-ERG9HA] strain grown at 319 
the same temperature (Fig. 5a and b). The expression of all the tested genes of sterol 320 
biosynthesis was induced (Fig. 5a), except for the HMG2 gene which is one of the yeast 321 
paralogues coding for HMG-CoA reductase. The expression of genes coding for 322 
enzymes of other mevalonate-end products was only slightly changed in the erg9Δ 323 
[PERG9-HYBHA] strain (Fig. 5b), the majority of them were down-regulated. 324 
 325 
The levels of squalene and sterols are lowered in HYBHA expressing strain 326 
cultured with inhibitors 327 
The constructed erg9Δ [PERG9-HYBHA] strain was used in further tests of two inhibitors 328 
of the mevalonate pathway: zaragozic acid – inhibitor of squalene synthase, and 329 
rosuvastatin – inhibitor of HMG-CoA reductase. They were chosen to compare the 330 
effect of the inhibition of the mevalonate pathway at the level of SQS and HMGR. To 331 
this end, median lethal dose of inhibitors (LD50) was assessed at permissive temperature 332 
of 28
oC. The final concentration of 1.3 µmol l-1 for zaragozic acid and 22.8 µmol l-1 for 333 
rosuwastatin were needed for 50% growth inhibition after 10 hours of cultivation. 334 
To determine the influence of zaragozic acid and rosuvastatin on squalene and 335 
sterol content in HYBHA expressing strain, GC-MS analysis was performed for lipids 336 
isolated from cells grown in the presence or absence of the respective inhibitor. As 337 
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expected, both inhibitors decreased the levels of squalene, lanosterol and ergosterol. 338 
The effect of rosuvastatin on sterol biosynthesis inhibition was higher than that of 339 
zaragozic acid at the same toxic dose of LD50. The amount of lipids was reduced to: 340 
4.6% vs 17.5% (p=0.032) for squalene, 4.3% vs 21.6% (p=0.005) for lanosterol and 341 
60% vs 80.8% (p=0.093) for ergosterol, by rosuvastatin and zaragozic acid, respectively 342 
(Fig. 6). 343 
 344 
Inhibition of the mevalonate pathway alters the expression of selected genes 345 
Rosuvastatin and zaragozic acid act at different points of the mevalonate pathway, 346 
might differently affect the availability of FPP. Rosuvastatin, by inhibition of the early 347 
step of the pathway, diminishes the cellular level of farnesyl diphosphate (Liao 2002). 348 
On the contrary, blocking the major FPP utilizing branch at the level of squalene 349 
synthase results in elevated FPP availability. Taking this into account, the expression of 350 
mevalonate pathway genes, especially genes from side branches in response to inhibitor, 351 
was followed. RT-qPCR analysis was performed for the erg9Δ [PERG9-HYBHA] strain 352 
cultured with or without the respective inhibitor. 353 
As was expected, genes of the early mevalonate pathway and sterol biosynthesis 354 
branch were up-regulated in response to both inhibitors (Fig. 7a, left diagram). On the 355 
contrary, the expression of genes of other isoprenoid pathway-end products, below the 356 
FPP-branching was mostly decreased, except for MOD5 (Fig. 7a, right diagram). 357 
Surprisingly, the tendency of changes in mRNA levels was consistent for both 358 
inhibitors. In order to check whether increased doses of inhibitors would enhance the 359 
changes in gene expression, RT-qPCR was performed for the HYBHA expressing strain 360 
inhibited with LD70 dose of rosuvastatin or zaragozic acid. Indeed, although the general 361 
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trend seemed similar, the rate of up- or down-regulation was better pronounced (Fig. 362 
7b) than in case of LD50. 363 
The mRNA level of hybrid squalene synthase was up-regulated in response to 364 
treatment with inhibitors (Fig. 7a and b). Also the level of SQS protein was slightly 365 
increased by both rosuvastatin and zaragozic acid (Supporting Information, Fig. S4). 366 
 367 
Discussion 368 
Since a comparison of modeled structures of yeast and human squalene synthases 369 
revealed substantial conformational differences close to the central cavity, a hybrid SQS 370 
was constructed. The human-yeast hybrid squalene synthase, containing 67% of human 371 
SQS aa, including the catalytic site, was expressed in Saccharomyces cerevisiae erg9Δ 372 
strain in order to define the utility of yeast as a tool for screening human SQS inhibitors. 373 
The ERG9 gene expression in yeast has been reported to undergo complex regulation, 374 
both positive and negative, by diverse factors through cis-elements in the promoter 375 
(Kennedy et al. 1999; Kennedy and Bard 2001). Using the native ERG9 promoter to 376 
drive expression of the hybrid SQS gene we ensured its proper regulation and 377 
expression. This is crucial because squalene synthase constitutes an important point of 378 
the mevalonate pathway, second to HMG-CoA reductase, that is regulated by a sterol 379 
feedback mechanism and is responsible for directing substrates to different branches of 380 
the pathway. 381 
Although during standard growth conditions the erg9Δ [PERG9–HYBHA] strain 382 
behaves like a control strain, it is resistant to nystatin. Nystatin was previously reported 383 
to be specific for ergosterol in yeast cell membranes (Walker-Caprioglio 1989), and 384 
sterol mutants (e.g. ERG7, ERG6, ERG5) are resistant to nystatin (SGD Database, 385 
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http://www.yeastgenome.org). This might suggest that qualitative or quantitative 386 
changes in sterol content of yeast cellular membranes are correlated with resistance to 387 
nystatin. GC-MS analysis, indeed, showed that the strain expressing hybrid SQS has 388 
diminished amount of squalene, lanosterol and ergosterol. 389 
Mevalonate pathway regulation is very complex and only partially understood, 390 
however, it is known to proceed at multiple levels, such as transcriptional activation and 391 
repression, maintaining protein stability or stimulating protein degradation, and it 392 
involves sterol and non-sterol intermediates of the pathway. In general, genes of the 393 
early part of mevalonate pathway as well as genes of sterol biosynthesis branch are 394 
overexpressed in the HYBHA expressing strain, except the MG2 gene, which is slightly 395 
down-regulated. We suspect that the overexpression is caused by a sterol-mediated 396 
feedback response, which has previously been reported both in mammalian and yeast 397 
cells (Dimster-Denk et al. 1994; Dimster-Denk et al. 1999). 398 
The second important regulation point of the mevalonate pathway resides at the 399 
level of FPP, which is considered as the common precursor for numerous isoprenoids. 400 
The expression of genes placed in the intersectional pathways (shown in Fig. 1) is 401 
generally decreased in the erg9Δ [PERG9–HYBHA] strain. Perhaps the underlying reason 402 
is an effort of cells to redirect the flux of FPP to the impaired sterol biosynthetic 403 
pathway or a rescue mechanism in response to possibly increased level of farnesyl 404 
diphosphate. 405 
In summary, the yeast strain expressing the hybrid SQS contains a lower level of 406 
sterols than the control strain although the amount of sterols is sufficient to maintain 407 
normal growth at standard growth conditions. The diminished level of sterols triggers 408 
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an adaptive response of the cell, which includes an overexpression of the mevalonate 409 
pathway and sterol biosynthesis branch genes.  410 
We tested two inhibitors acting at different enzymes of the mevalonate pathway, 411 
namely rosuvastatin and zaragozic acid that inhibit HMG-CoA reductase and squalene 412 
synthase, respectively. A rationale for this selection was a possible contrapositive effect 413 
on the pool of farnesyl diphosphate exerted by HMG-CoA and SQS inhibitors.  414 
Inhibition of mevalonate pathway either at the level of HMGR or SQS affects 415 
the synthesis of squalene and finally sterol production in the erg9Δ [PERG9–HYBHA] 416 
strain. The most significant reduction was seen for ergosterol biosynthetic precursors, 417 
such as squalene and lanosterol. On the contrary, the last product of the branch, 418 
ergosterol, was only slightly decreased, which might be caused by efficient conversion 419 
of precursors and mobilisation of sterol stored in lipid particles. Rosuvastatin appears to 420 
impair sterol biosynthesis to a greater extent than zaragozic acid when compared at 421 
LD50. Sensitivity of the erg9Δ [PERG9–HYBHA] strain to mevalonate pathway inhibitors 422 
proves that this strain may be successfully used for SQS inhibitor screening. 423 
Rosuvastatin and zaragozic acid induced the expression of genes of the early 424 
steps of mevalonate pathway (except the HMG2 gene) and genes specific for sterol 425 
synthesis. The enhanced expression was most likely related to the feedback response 426 
triggered by decreased amounts of sterol. A similar effect on the expression of genes 427 
along the mevalonate pathway in yeast observed during HMG-CoA and SQS inhibition 428 
was reported by Dimster-Denk et al. (1999) and Kuranda et al. (2010). Due to an 429 
opposite effect of the inhibition of HMGR and SQS, expected on FFP level, we 430 
followed the mRNA levels of genes from the branching pathways for rosuvastatin and 431 
zaragozic acid blocks. Inhibition of HMGR leads to a decreased amount of mevalonic 432 
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acid and depletion of downstream products along with farnesyl diphosphate (Liao 433 
2002), which becomes less available for enzymes utilizing FPP. On the contrary, the 434 
SQS block results in an elevated FPP level (Bergstrom et al. 1993), that may be more 435 
accessible for FPP-consuming enzymes. We observed negligible effect of the inhibition 436 
on BTS1 and RER2 expression, but the levels of RAM1, COQ1 and COX10 mRNA were 437 
diminished in both tested strains. However, the directions of expression changes for 438 
specific genes were consistent for both inhibitors, which is most likely related to the 439 
influence of deficient sterols. Also the expression of other genes in branching pathways 440 
was repressed, such as ubiquinone biosynthesis genes (COQ3, CAT5), dolichyl 441 
phosphate biosynthesis gene (SEC59) and the gene coding for a protein that undergoes 442 
farnesylation, RAS1. The only genes that were up-regulated were COQ2 and MOD5, of 443 
which the first is involved in ubiquinone biosynthesis and the second is responsible for 444 
tRNA prenylation process. The alterations in the expression levels were even higher 445 
when the growth of HYBHA bearing strain was inhibited by 70% what indicates that the 446 
constructed strain demonstrates a dose – response effect. 447 
Saccharomyces cerevisiae model that has been engineered in this study is a 448 
convenient tool for high-throughput screening for molecules designed to inhibit the 449 
catalytic site of human SQS. Moreover, the yeast model allows to study the 450 
physiological and molecular effects of tested molecules on the cell, such as mRNA and 451 
protein expression levels and lipid profile.  452 
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Figure legends 584 
 585 
Figure 1 The biosynthesis of ergosterol (yeast) and cholesterol (human). The enzymes 586 
selected for gene expression analysis are shown at the corresponding steps of the 587 
pathway. ARE1 – sterol O-acyltransferase 1, ARE2 – sterol O-acyltransferase 2, BTS1 – 588 
geranylgeranyl diphosphate synthase, CAT5 – ubiquinone biosynthesis monooxygenase, 589 
COQ1 – hexaprenyl diphosphate synthase, COQ2 – para-hydroxybenzoate-polyprenyl 590 
transferase, COQ3 – 3,4-dihydroxy-5-hexaprenylbenzoatemethyltransferase, COX10 – 591 
protoheme IX farnesyltransferase, ERG1 – squalene monooxygenase, ERG10 – acetyl-592 
CoA acetyltransferase, ERG20 – farnesyl diphosphate synthase, ERG3 – C-5 sterol 593 
desaturase, ERG6 – delta(24)-sterol C-methyltransferase, ERG9 – squalene synthase, 594 
FDT1 – squalene synthase (human), HMG1 – 3-hydroxy-3-methylglutaryl-Co A 595 
reductase 1, HMG2 – 3-hydroxy-3-methylglutaryl-Co A reductase 2, MOD5 – tRNA 596 
dimethylallyltransferase, RAM1 – protein farnesyltransferase subunit beta, RAM2 – 597 
protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha, RER2 – cis-598 
prenyltransferase, SEC59 – dolichol kinase. ZA – zaragozic acid. 599 
 600 
Figure 2 Structural comparison of human and hybrid SQS. Human protein is in green, 601 
hybrid in blue (light blue for human part, dark blue for yeast part). Active center is 602 
highlighted in yellow. Zaragozic acid is presented as sticks. Arrows indicate main 603 
differences between human and hybrid SQS structures. 604 
 605 
Figure 3 The HYBHA hybrid gene complements the ERG9 gene. (a) Serial dilutions of 606 
the BY4741 strain bearing the empty vector, and both ERG9HA and HYBHA expressing 607 
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strains were spotted on YPD, minimal, glycerol and ethanol medium. Strains were 608 
grown at 28C. (b) The growth curve of ERG9HA and HYBHA expressing strains grown 609 
in minimal liquid medium (without histidine) for 14 hours at 28C. (   ) erg9Δ [PERG9-610 
ERG9HA] and (   ) erg9Δ [PERG9-HYBHA]. (c) The HYBHA expressing strain is resistant 611 
to nystatin. Serial dilutions of the tested strains were spotted on YPD and YPD 612 
supplemented with nystatin. Strains were grown at 28C. 613 
 614 
Figure 4 Analysis of lipids. (a) The content of squalene and sterols in the HYBHA strain 615 
is diminished in comparison to the control strain. Strains were cultured in minimal 616 
(histidine lacking) medium at 28C for 10 hours and lipid content was analyzed by 617 
GC/MS. (   ) erg9Δ [PERG9-ERG9HA]; (  ) erg9Δ [PERG9-HYBHA] and (*) p≤0.05. (b) 618 
The lipid profile is changed in the HYBHA strain comparing to the control strain. Strains 619 
were cultured at 28
o
C for 10 hours, lipids were extracted and separated on TLC plates. 620 
Numbers represent the ratio of the lipid in HYBHA expressing strain with respect to the 621 
control strain. One representative analysis of three independent TLC experiments is 622 
shown. (E) erg9Δ [PERG9-ERG9HA]; (H) erg9Δ [PERG9-HYBHA]; (SQ) squalene; (SE) 623 
sterol esters; (TAG) triacylglycerols; (FFA) free fatty acids and (ERG) ergosterol. 624 
 625 
Figure 5 mRNA levels of selected genes encoding enzymes of sterol and nonsterol 626 
biosynthesis pathways. (a) and (b) The expression of genes in the erg9Δ [PERG9-627 
HYBHA] strain relative to the expression in the control strain cultured at 28
o
C. mRNA 628 
levels of genes coding for enzymes of the mevalonate pathway (1) above FPP and (2) 629 
sterol biosynthesis are indicated on the right panel. mRNA levels of genes coding for 630 
enzymes that participate in (3) protein prenylation, (4) ubiquinone biosynthesis, (5) 631 
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dolichol biosynthesis, (6) heme A biosynthesis, and (7) tRNA prenylation are indicated 632 
on the left panel. Expression data were normalized to ACT1 gene. Results are shown as 633 
a log2 of relative expression. (*) p≤0.05 and (**) p≤0.001. 634 
 635 
Figure 6 The reduction of squalene and sterol content in HYBHA expressing strain is 636 
dependent on the type of inhibitor used. The erg9Δ [PERG9-HYBHA] strain was cultured 637 
in minimal (histidine lacking) medium at 28C for 10 hours with (   ) rosuvastatin or (   ) 638 
zaragozic acid. % of sterol concentration in comparison to the “no treatment” group. 639 
 640 
Figure 7 The expression of genes in the erg9Δ [PERG9-HYBHA] strain exposed to the 641 
inhibitor relative to the expression in unexposed cells. Yeast cells were cultured at 28
o
C 642 
for 10 hours in the presence or absence of the respective inhibitor at the dose of (a) LD50 643 
or (b) LD70. mRNA levels of genes coding for enzymes of the mevalonate pathway (1) 644 
above FPP and (2) sterol biosynthesis branch are indicated on the right panel. mRNA 645 
levels of genes coding for enzymes that participate in (3) protein prenylation, (4) 646 
ubiquinone biosynthesis, (5) dolichol biosynthesis, (6) heme A biosynthesis, and (7) 647 
tRNA prenylation are indicated on the left panel. Expression data were normalized to 648 
ACT1 gene. Results are shown as a log2 of relative expression. (  ) rosuvastatin; (   ) 649 
zaragozic acid; (*) p≤0.05 and (**) p≤0.001. 650 
651 
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Supporting Information 652 
 653 
Table S1 Primers used for plasmid construction 654 
Table S2 Yeast strains used in this study 655 
Table S3 Sequences of primers used in real-time PCR 656 
Supporting Materials and methods: Construction of the ERG9HA strain 657 
Supporting Materials and methods: Immunodetection of HA-tagged squalene 658 
synthase 659 
Figure S1 The methodology of plasmid construction. (a) Construction of hybrid 660 
squalene synthase coding sequence (HYB). (b) Construction of PERG9-yHYBHA/pRS313 661 
plasmid. 662 
Figure S2 Human SQS ribbon model. DXXED conserved motifs are highlighted in 663 
light blue and loops S51-F54 and V314-K318 in dark blue (Liu et al. 2014). Changes in 664 
the main chain course for yeast SQS are shown in red; non conserved residues of N113-665 
D119 and D161-T171 fragments are shown as sticks. 666 
Figure S3 Alignment of yeast (Y) and human (H) SQS amino acid sequences. The 667 
hybrid human-yeast SQS protein consists of amino acid residues 1-296 of human SQS 668 
and residues 304-444 of yeast SQS. Arrow indicates the exchanged regions. Stars 669 
indicate identical amino acid residues. Sequences were aligned using the COBALT 670 
server (Papadopoulos and Agarwala 2007). 671 
Figure S4 The steady-state squalene synthase protein (SQS-HA) level in the erg9Δ 672 
[PERG9–HYBHA] strain. 673 
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